Please assess the completion status of the following clinical trial:

Trial Title: A Study of Vincristine, Escalating Doses of Irinotecan, Temozolomide and Bevacizumab (Vit-b) in Pediatric and Adolescent Patients With Recurrent or Refractory Solid Tumors of Non-hematopoietic Origin

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Age: Patients must be \> 12 months and \< 21 years of age at the time of study entry.~* Weight: Patient must be more than or equal to 10 Kilograms.~Histological Diagnosis:~* Patients must have had histological verification of the malignancy at some time prior to study entry.~* All solid tumors are eligible with the exclusion of lymphomas. For patients with neuroblastoma, diagnosis based on elevated catecholamines in the urine and tumor cells on bone marrow aspirates/biopsies is acceptable.~* For patients with germ cell tumors, diagnosis based on elevated tumor markers (serum alpha fetoprotein and/or serum beta human chorionic gonadotropin) and radiographic evidence of disease is acceptable.~Disease Status:~* Disease must have failed standard therapy (therapies) or be a disease for which no standard therapy exists.~* Patient with stable disease on other therapies are not eligible.~Performance Level:~* Karnofsky \> 50% for patients \>16 years of age and Lansky \> 50 for children \< 16 years of age (Appendix I).~* Life Expectancy: Must be \> 8 weeks.~Exclusion Criteria:~* Patients who have received bevacizumab and/or Irinotecan previously are ineligible. Non brain tumor patients who have previously received Temozolomide are ineligible.~* Pregnancy or Breast-Feeding: Pregnant patients are ineligible for this study due to the known teratogenic effects of the cytotoxic agents. Pregnancy tests must be obtained in females of childbearing potential prior to enrollment.~* Lactating women must agree not to breast-feed.~* Males or females of reproductive age may not participate unless they have agreed to use an effective contraceptive method.~* Patients Who Have an Uncontrolled Infection will not be eligible for enrollment until all infections are under control.~* Clinically Significant Unrelated Systemic Illness: Patients with serious infections or significant pulmonary, hepatic, renal, or other end-organ dysfunction which in the judgment of the Principal or Co-Investigators would compromise the patient's ability to tolerate prescribed chemotherapy or are likely to interfere with the study procedures or results will not be eligible.

- Gender: ALL
- Minimum Age: 12 Months
- Maximum Age: 20 Years
- Healthy Volunteers: f

Study Arms:
- Single Arm (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).